New antibiotic strategy targets deadly infections in vulnerable patients
NCT ID NCT04673175
First seen Jan 28, 2026 · Last updated Jun 13, 2026 · Updated 23 times
Summary
This study tested whether the antibiotic ceftolozane-tazobactam can effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. Participants received the drug through a vein every 8 hours for 10 to 14 days. Researchers tracked survival and infection improvement at 30 and 60 days. The study was stopped early and included a historical control group for comparison.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.